Chief Scientific Officer

Dr Brendon Monahan

Dr. Monahan has over 15 years research experience in molecular genetics in various biological systems, with a particular focus on gene regulation and epigenetics. Following the completion of his PhD at the University of Melbourne, and post-doctoral positions at Massey University (New Zealand), and Harvard Medical School (Boston, USA), Brendon joined CSIRO in 2008 and was first involved with CTx in 2010, leading the CSIRO team that produced protein resources for CTx.

Brendon is based at the Walter and Eliza Hall Institute (WEHI) and is involved in the identification, scoping and engagement of new projects for the CTx drug discovery portfolio. In August 2017, Brendon was appointed to Deputy Chief Scientific Officer and commenced the role of Chief Scientific Officer in November 2018.